106,654 Shares in Progyny, Inc. $PGNY Bought by Empowered Funds LLC

Empowered Funds LLC bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY) in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 106,654 shares of the company’s stock, valued at approximately $1,811,000. Empowered Funds LLC owned approximately 0.14% of Progyny at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of PGNY. Caitong International Asset Management Co. Ltd bought a new stake in shares of Progyny in the fourth quarter valued at about $25,000. Hantz Financial Services Inc. grew its holdings in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Progyny during the second quarter worth about $77,000. Quarry LP raised its position in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares during the last quarter. Finally, New Age Alpha Advisors LLC acquired a new stake in Progyny in the 4th quarter valued at approximately $94,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Price Performance

NASDAQ:PGNY opened at $30.21 on Friday. The company has a market cap of $2.37 billion, a P/E ratio of 39.23, a P/E/G ratio of 2.49 and a beta of 1.01. The firm’s fifty day moving average price is $29.02 and its two-hundred day moving average price is $23.40. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $348.63 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. Progyny’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts expect that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny declared that its board has authorized a stock repurchase program on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 10.3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

PGNY has been the subject of several research reports. Weiss Ratings raised shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. KeyCorp boosted their price objective on shares of Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Leerink Partners set a $38.00 target price on shares of Progyny in a research report on Wednesday, July 22nd. Finally, Bank of America lifted their price target on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.25.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Second-quarter adjusted earnings were $0.55 per share, well above the reported consensus estimates of $0.33 and $0.51, and up from $0.19 a year earlier. Revenue reached $350.5 million, exceeding the $348.6 million consensus estimate and rising 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Progyny raised or reaffirmed a favorable full-year outlook, forecasting 2026 earnings of $2.04–$2.10 per share, above the $1.86 analyst consensus. Full-year revenue guidance of approximately $1.4 billion was broadly in line with expectations. Progyny Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: The quarter showed improved profitability, with reported net margin of 5.23% and return on equity of 13.34%, potentially supporting the company’s earnings trajectory. Progyny Earnings Report and Conference Call
• Neutral Sentiment: Third-quarter EPS guidance of $0.50–$0.52 exceeded the $0.47 consensus, indicating continued earnings strength.
• Negative Sentiment: Third-quarter revenue guidance of $335 million–$345 million fell below the $350.2 million analyst estimate. The softer near-term top-line outlook may have outweighed the earnings beats, particularly with PGNY trading at a relatively elevated valuation and near its 12-month high. Progyny Q2 CY2026 Results and Stock Reaction

Insider Activity

In other news, insider Geoffrey Clapp sold 1,530 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin K. Gordon sold 5,500 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total value of $137,445.00. Following the transaction, the director owned 9,318 shares in the company, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 36,916 shares of company stock valued at $939,875. Company insiders own 9.90% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.